🟢 VANI is trading 7.8% up today on Novo Nordisk deal to evaluate semaglutide implant

VANI is trading 7.8% up at $1.46 after announcing an agreement with Novo Nordisk to evaluate NPM-139, a semaglutide implant for chronic weight management.

• The collaboration serves as a major validation of Vivani’s proprietary NanoPortal implant platform.
• The move extends a 5.4% surge from the previous session, maintaining strong investor momentum following the deal announcement.